Brief case series: Montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis

Abstract

Montelukast, at doses recommended for asthma treatment, resulted in over 30% reduction in the total SCORAD in some children. Treatment with montelukast may also be associated with deviation of the immune system towards the Th1-specific pathway.

Does age or gender influence quality of life in children with atopic dermatitis?

“…The optimum recommendations for bathing and treatments with emollients, antihistamines, topical corticosteroids, calcineurin inhibitors, systemic antibiotics and various alternative therapies remains a major challenge for physicians caring for children with this distressing disease. [13][14][15][16][17][18][19] Surprisingly, problems with friendship, school ⁄ holidays, and teasing ⁄ bullying only occurred in a minority (< 10%) of children, and no age and gender disparities were observed. The exact reasons for these were not clear.…”

A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema

“…Initial clinical observations on the effects of this approach have been encouraging [6][7][8][9]. There are also encouraging reports on the use of other anti-leukotriene agents such as zafirlukast [10] and zileuton [11].…”

Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?

“…Also, use of traditional and proprietary herbal medicines for atopic diseases is popular 20,21. Noncorticosteroid-based medications such as montelukast may play a role in better control for various atopic diseases in some of these cities 22,23…”